Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.
about
Invasive candidiasis as a cause of sepsis in the critically ill patientEpidemiological trends in nosocomial candidemia in intensive careActivities of fluconazole and voriconazole against 1,586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001Trends in antifungal susceptibility of Candida spp. isolated from pediatric and adult patients with bloodstream infections: SENTRY Antimicrobial Surveillance Program, 1997 to 2000.International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY antimicrobiaAntifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study.Candidaemia and antifungal therapy in a French University Hospital: rough trends over a decade and possible links.Preliminary evaluation of a semisolid agar antifungal susceptibility test for yeasts and molds.Trends in antifungal susceptibility among Candida sp. Urinary isolates from 1994 and 1998.The ATP binding cassette transporter gene CgCDR1 from Candida glabrata is involved in the resistance of clinical isolates to azole antifungal agents.Differential antifungal activity of isomeric forms of nystatinLactoferrin peptide increases the survival of Candida albicans-inoculated mice by upregulating neutrophil and macrophage functions, especially in combination with amphotericin B and granulocyte-macrophage colony-stimulating factor.In vitro and in vivo antifungal activities of TAK-456, a novel oral triazole with a broad antifungal spectrum.Potato dextrose agar antifungal susceptibility testing for yeasts and molds: evaluation of phosphate effect on antifungal activity of CMT-3Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007Economic considerations of antifungal prophylaxis in patients undergoing surgical proceduresPrevalence of Candida species, including Candida dubliniensis, in Singapore.Antifungal resistance of Candida glabrata vaginal isolates and development of a quantitative reverse transcription-PCR-based azole susceptibility assay.Trends in species distribution and susceptibility of bloodstream isolates of Candida collected in Monterrey, Mexico, to seven antifungal agents: results of a 3-year (2004 to 2007) surveillance study.Expression of mouse beta defensin 2 in escherichia coli and its broad-spectrum antimicrobial activity.Substitution of methionine 63 or 83 in S100A9 and cysteine 42 in S100A8 abrogate the antifungal activities of S100A8/A9: potential role for oxidative regulation.Rapid identification of Candida species by confocal Raman microspectroscopy.Inactivation of transcription factor gene ACE2 in the fungal pathogen Candida glabrata results in hypervirulence.Clinical Significance of Candida in an Intraoperative Peritoneal Specimen with Perforation Peritonitis: An Institutional Perspective.Synergistic and antagonistic effects of immunomodulatory drugs on the action of antifungals against Candida glabrata and Saccharomyces cerevisiae.
P2860
Q22305429-8A52AB82-4188-47AF-B6C7-810A86321769Q25255762-FB26C56C-9B73-4262-9187-61B1E85821CFQ30452998-2B5F0EA9-B3ED-4809-858B-F4B282E60584Q30453032-93D13E31-3777-49D9-9C73-B587BF86C0F2Q30453797-03B3ECE4-7BF3-4D4E-B319-23A05E286AACQ30981454-3F807F56-A8F7-4C7E-939B-DBA278693789Q33183542-F84530EA-E800-4544-905D-7CD4955E7FABQ33241991-D3B4F405-A218-4816-B54A-62C8A9E1084EQ33965280-1D75A972-D9AC-4D74-8A23-CAB1BAEA1262Q33965636-294CCEAB-176B-452D-91D7-89EF667CA43CQ33978099-B578DE41-0582-4FDD-A897-A08A52A6465CQ33983112-62E13B52-A972-4322-BF6E-EDE5B834CB2DQ34007871-9422AABE-A6EE-4CFB-A6D6-DE59DDA03665Q34106775-04D1C3A4-278D-4DC4-9097-E698C87BAE6AQ34107468-667517C0-5287-4E99-83CA-3032DF79B3FBQ34332272-886885CA-F030-4B85-9E67-44A8370CE439Q34574154-73CD1042-4415-41C9-8530-3B804825F36BQ34747519-30A63210-4D94-48CD-9CA0-D414A6684824Q36870890-2FA69632-FBE8-4536-8C2E-734634170272Q36898200-349A55F8-42C2-42BE-9DB7-E97142F85AD6Q37159784-C829F8AF-44A6-4D20-97F0-0F217983CC34Q37315186-CB679C24-A880-46F6-BF59-BA4D1EAAB74AQ39746568-D71406F7-8081-4235-9156-77BE2F44FD2BQ40763002-C1CDAE4F-6016-4F57-9202-D1248EC8B1ACQ54218643-772D87E2-B4B8-4149-A3BE-0E8093209F05Q55313368-A9FCE29A-5078-4B89-ABD0-8C8C1A4C95D1
P2860
Trends in antifungal use and epidemiology of nosocomial yeast infections in a university hospital.
description
1999 nî lūn-bûn
@nan
1999 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի մարտին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Trends in antifungal use and e ...... ions in a university hospital.
@ast
Trends in antifungal use and e ...... ions in a university hospital.
@en
type
label
Trends in antifungal use and e ...... ions in a university hospital.
@ast
Trends in antifungal use and e ...... ions in a university hospital.
@en
prefLabel
Trends in antifungal use and e ...... ions in a university hospital.
@ast
Trends in antifungal use and e ...... ions in a university hospital.
@en
P2093
P2860
P1476
Trends in antifungal use and e ...... tions in a university hospital
@en
P2093
L A Herwaldt
M A Pfaller
Y F Berrouane
P2860
P304
P407
P577
1999-03-01T00:00:00Z